Study Complete
Sponsor ID
20010238
A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
Study Details
This clinical study is investigating AMG 719, an investigational drug, for the treatment of patients who have Rheumatoid Arthritis and who are taking Methotrexate. AMG 719 is a drug which is self-injected beneath the skin (similarly to the way insulin is self-injected by diabetics). Patients on this study are on study for 28-weeks. They visit the study facility at least 11 times while participating in the study.
Protocol Summary
Primary Outcome Measures
AMG 719 has a favorable safety profile in subjects with RA receiving methotrexate.
Timeframe: Week 24
Secondary Outcome Measures
To assess the effects of multiple doses of AMG 719 relative to placebo on signs and symptoms of RA
Timeframe: Week 24
Locations
No locations found.